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Acromegaly is a chronic state of growth hormone (GH) excess, usually due to a GH-secreting pituitary tumor. Insulin-like growth factor I (IGF-I) mediates many of the effects of GH (1) , and has anabolic actions as well as hypoglycémie effects like insulin (2) . Hepatic IGF-I production is regulated by GH (1) . Unlike GH levels, IGF-I levels vary little through¬ out the day (1) . The serum IGF-I level is a reliable parameter of excessive GH secretion in active acro¬ megaly (3, 4) .
In the circulation, more than 90% of plasma IGF-I is complexed to specific binding proteins (IGFBPs) (5) , which modify the biological activity of IGF-I. The 28-kD fGFBP-1 is generally found to be an inhibitor of IGF-I actions, although some stimulatory effects of IGFBP-1 have been described (6) . In vitro, IGFBP-1 secretion has been shown to be regulated primarily by insulin (6) .
Fasting levels of insulin and ÍGFBP-1 are correlated inversely in children and young adults (7) . However, in aged individuals this correlation seems to disappear (7) . Furthermore, IGF-I levels decrease with age, reflecting a diminished GH secretion (8) (9) (10) . Previous studies have shown either normal or lowered IGFBP-1 levels in patients with active acromegaly as compared to healthy controls (8, (11) (12) (13) .
In the case of persistently increased GH levels following neurosurgery for GH-producing pituitary tumors, adjunctive medical therapy is necessary. The dopamine agonists bromocriptine and quinagolide and the cyclic somatostatin analogs octreotide and lanreotide have been used to attenuate effectively both GH and IGF-I excess in acromegaly (14) (15) (16) (17) (18) (19) .
In cultured hepatoma (hep G2) cells, octreotide induces IGFBP-1 production. This stimulation seems to occur independent of GH and insulin concentra¬ tions (20) .
In a number of different clinical settings several investigators have shown that the administration of native somatostatin 14 (SS-14), octreotide or lanreotide to healthy young subjects, GH-deficient subjects and acromegalics was followed by an increase in circulating IGFBP-1 levels (12, 13, (21) (22) (23) (24) . In a few studies an inverse correlation between circulating IGFBP-1 and insulin levels was found (12, 21) 
